Abstract:OBJECTIVE To evaluate the dosing regimens of levofloxacin. METHODS The drug concentrations in serum and urine were assayed by HPLC method and the pharmacokinetic parameters were calculated after intravenous infusion of a single dose of 200 mg, 300 mg and 500 mg levofloxacin to healthy volunteers. The in vitro activity MIC of levofloxacin against 823 clinical isolates were determined and compared with other antimicrobial agents. Based on the above results, the PK/PD parameters C(max)/MIC and AUC/MIC were calculated and the dosing regimens of levofloxacin were proposed for infections caused by different pathogens. RESULTS The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg. The in vitro pharmacodynamic study showed that levofloxacin was highly active against Hemolytic streptococcus and Moraxella catarrhalis. It was active against Streptococcus pneumoniae (including penicillin nonsusceptible strains), Hemophilus influenzae, methicillin-sensitive Staphylococcus aureus (MSSA), Klebsiella pneumoniae and Stenotrophomonas maltophilia. Levofloxacin also had good activity against Pseudomonas aeruginosa and K.pneumoniae. However, most of isolates of enterococcal spp. were resistant to levofloxacin. Above 50% of Escherichia coli isolates were resistant to levofloxacin. Based on the results of PK/PD parameters, the adequate dosing regimens of levofloxacin should be once daily 200 mg once daily of levofloxacin was expected to be effective for the treatment of infections caused by M. catarrhalis. The regimen of 300 mg once daily could be effective for the treatment of infections caused by Hemolytic streptococcus. 500 mg once daily of levofloxacin was expected to be effective for the treatment of respiratory tract infections caused by S. pneumoniae or H. influenzae. For treatment of respiratory tract infections and urinary tract infections caused by levofloxacin-susceptible organisms including K. pneumoniae, E. coli, P. aeruginosa, and S.maltophilia, 500 mg once daily of levofloxacin was needed to obtain good clinical efficacy. But PK/PD parameters predicted that 500 mg daily of levofloxacin was not effective for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci. CONCLUSION The proposed dosing regimens of levofloxacin based on PK/PD concepts are expected to provide good efficacy in clinical practice.

PHARMACOKINETICS AND BIOAVAILABILITY OF CLINAFLOXACIN IN RATS

Determination of Clinafloxacin in Rat Plasma by HPLC

Influence of Pazufloxacin Mesilate on Pharmacokinetics of Aminophylline in Rabbits

Pharmacokinetics of gatifloxacin mesylate and gatifloxacin in rats in vivo

Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: Contribution of gastric first-pass effect to low bioavailability

Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers.

Intrapulmonary concentration of ciprofloxacin in patients of lower respiratory tract infection with ventilation support

Pharmacokinetics/pharmacodynamics of Antofloxacin Hydrochloride in a Neutropenic Murine Thigh Model Ofstaphylococcus Aureusinfection

Absolute bioavailability of levofloxacin tablet in healthy Chinese male subjects

Pharmacokinetics of Antofloxacin Hydrochloride, a Novel Fluoroquinolone, after Single-Dose Intravenous Administration in Healthy Chinese Male Volunteers.

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

Studies on clinical pharmacokinetics of domestic fleroxacin

RP-HPLC analysis of flucloxacillin in human plasma: validation and application to a bioequivalence study.

A Randomized Study of the Single-Dose Safety, Pharmacokinetics, and Food Effect of Chinfloxacin and Its Effect on Thorough QT/QTc Interval in Healthy Chinese Volunteers

Pharmacokinetics of Antofloxacin Hydrochloride in Healthy Male Subjects after Multiple Intravenous Dose Administration.

A Simple LC/MS/MS Method for the Determination of Moxifloxacin N-Sulfate in Rat Plasma and Its Application in a Pharmacokinetic Study.

In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin Against Klebsiella Pneumoniae in a Neutropenic Murine Lung Infection Model.

Pharmacokinetic Study of Single and Multiple Oral Dose Administration of Antofloxacin Hydrochloride in Healthy Male Volunteers.

[Study of Pharmacokinetics/pharmacodynamics of Levofloxacin].

Tolerability and Pharmacokinetics of Antofloxacin Hydrochloride after Multiple Oral Dose Administration in Healthy Chinese Male Volunteers.

A Phase Ii Study of Antofloxacin Hydrochloride, A Novel Fluoroquinolone, for the Treatment of Acute Bacterial Infections